Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2007 1
2008 2
2009 2
2010 3
2011 2
2012 1
2013 1
2014 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease.
Kjoller E, Hilden J, Winkel P, Frandsen NJ, Galatius S, Jensen G, Kastrup J, Hansen JF, Kolmos HJ, Jespersen CM, Hildebrandt P, Gluud C; CLARICOR Trial Group. Kjoller E, et al. Among authors: jespersen cm. J Clin Epidemiol. 2012 Apr;65(4):444-53. doi: 10.1016/j.jclinepi.2011.09.011. Epub 2012 Jan 17. J Clin Epidemiol. 2012. PMID: 22257841 Clinical Trial.
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease.
Jensen GB, Hilden J, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group. Jensen GB, et al. Among authors: jespersen cm. J Cardiovasc Pharmacol. 2010 Feb;55(2):123-8. doi: 10.1097/FJC.0b013e3181c87e37. J Cardiovasc Pharmacol. 2010. PMID: 19920766 Clinical Trial.
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; CLARICOR Trial Group. Kastrup J, et al. Among authors: jespersen cm. Eur Heart J. 2009 May;30(9):1066-72. doi: 10.1093/eurheartj/ehp049. Epub 2009 Mar 6. Eur Heart J. 2009. PMID: 19270316 Free article. Clinical Trial.
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial.
Hilden J, Lind I, Kolmos HJ, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Jensen GB, Kastrup J, Kjøller E, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group. Hilden J, et al. Among authors: jespersen cm. Diagn Microbiol Infect Dis. 2010 Apr;66(4):385-92. doi: 10.1016/j.diagmicrobio.2009.11.011. Diagn Microbiol Infect Dis. 2010. PMID: 20226329 Clinical Trial.
Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial.
Kjøller E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, Fischer Hansen J, Kastrup J, Jespersen CM, Hildebrandt P, Kolmos HJ, Gluud C; CLARICOR Trial Group. Kjøller E, et al. Among authors: jespersen cm. Am Heart J. 2014 Aug;168(2):197-204.e1-4. doi: 10.1016/j.ahj.2013.12.032. Epub 2014 May 4. Am Heart J. 2014. PMID: 25066559 Clinical Trial.
High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group. Harutyunyan MJ, et al. Among authors: jespersen cm. Scand J Clin Lab Invest. 2011 Feb;71(1):52-62. doi: 10.3109/00365513.2010.538081. Epub 2010 Nov 25. Scand J Clin Lab Invest. 2011. PMID: 21108561 Clinical Trial.
14 results